Quironsalud Madrid
Tongue cancer treatment cost in Spain typically involves essential diagnostic steps like a PET-CT scan which runs from $1,300 to $1,800. Primary surgical interventions, such as tongue cancer surgery, generally cost between $18,000 and $30,000. Total expenses depend on tumor stage, the need for reconstruction, and hospital tier. Patients often find 30-40% savings compared to the US. Top treatment centers are located in Barcelona and Madrid.
Typical Tongue Cancer Treatment Costs in Spain
Bookimed Expert Insight: For complex cases requiring advanced technology, JCI-accredited centers like Hospital Quiron Barcelona offer integrated PET-CT and MRI staging. Patients seeking international expertise benefit from collaborations with leading American oncology institutes available at Quiron centers. For those interested in innovative therapies, Quironsalud Madrid provides unique access to clinical trials. Early-stage patients should prioritize high-volume surgical centers like Centro Médico Teknon for optimal outcomes.
| Turkey | Austria | Spain | |
| Tongue cancer surgery | from $9,000 | from $35,000 | from $18,000 |
| Partial Glossectomy | from $5,500 | - | - |
| Halcyon | from $5,400 | - | - |
Dr. López-Ibor specializes in pediatric oncology with over 32 years of experience of experience, currently leading the Pediatric Hematology and Oncology Unit at HM Montepríncipe Hospital.
The doctor is a pediatric oncologist with 37 years of experience, specializing in the treatment of blood disorders and performing procedures like bone marrow transplants and ablation therapy. The doctor is currently the Head of Paediatric Haemato-Oncology at Quironsalud Madrid University Hospital.
With a prolific academic record, the doctor has edited 14 books, contributed to 75 book chapters, and presented at over 200 conferences. The doctor is a member of several professional associations, including the Spanish Association of Paediatric Haematology and the Spanish Association of Paediatric Oncology.
The doctor treats a wide range of conditions, including leukemia, lymphoma, multiple myeloma, and various hematological and autoimmune disorders.
The doctor is responsible for thoracic malignancy management and oversees thoracic cancer trials at the Oncology Department. Their research focuses on optimizing chemotherapy in early-stage disease, evaluating new therapies, exploring pharmacogenomic approaches, integrating immunotherapy for lung cancer, and investigating resistance mechanisms to tyrosine-kinase inhibitors.
Holding a medical degree and a PhD in medical oncology from UAB, the doctor is a member of several prestigious oncology societies, including ESMO, ASCO, and IASLC. They have published numerous peer-reviewed articles and book chapters on thoracic malignancies and have held teaching positions at UAB and UVicc-UCC.
The doctor is an accomplished educator and researcher in the field of oncology, with extensive teaching experience at USP CEU. The doctor has taught a wide array of subjects including General Medical Pathology, Oral and Maxillofacial Oncology, and Bioethics. As a tutor for medical students and external rotants, the doctor has contributed significantly to the training of future healthcare professionals.
Additionally, the doctor holds the position of Director of postgraduate research in clinical and applied oncology at HM CIOCC USP CEU and is responsible for postgraduate master practices. The doctor has also completed advanced courses at MD Anderson Cancer Center.